SOFA – Page 12 – Communicable Diseases Research

Preemptive interleukin-6 blockade in patients with COVID-19

Article

Published on 2020-10-082022-10-04
Journal: Scientific Reports [Category] MERS, SARS, 바이오마커, 치료제,

Lactate Kinetics Reflect Organ Dysfunction and Are Associated with Adverse Outcomes in Intensive Care Unit Patients with COVID-19 Pneumonia: Preliminary Results from a GREEK Single-Centre Study

Article

Published on 2020-09-282022-10-30
Journal: Metabolites [Category] COVID-19,

Lung ultrasound score in establishing the timing of intubation in COVID-19 interstitial pneumonia: A preliminary retrospective observational study

Research Article

Published on 2020-09-032022-10-28
Journal: PLoS ONE [Category] COVID-19, MERS,

[키워드] 28-day mortality acute respiratory syndrome addition BMI changes in Characteristics condition coronavirus coronavirus disease COVID-19 Critical Critically ill patient died different time point effective evaluate female patient HFNC ICU in both groups individual intensive care interstitial interstitial pneumonia Intubated intubated patient intubation lung male material mechanical ventilation mechanically ventilated nasal nine NIV Non-intubated non-intubated patient Noninvasive ventilation oxygenation index PaO Patient patient groups per day Pneumonia respiratory rate Result retrospective SARS-CoV-2 SARS-CoV-2 pneumonia Seven severity significantly significantly higher SOFA the patient the timing treated two group two groups was performed worsened
[DOI] 10.1371/journal.pone.0238679 PMC 바로가기 [Article Type] Research Article

Disease progression patterns and risk factors associated with mortality in deceased patients with COVID‐19 in Hubei Province, China

Original Research

Published on 2020-08-282022-10-30
Journal: Immunity, Inflammation and Disease [Category] COVID-19, MERS, SARS,

[키워드] Acute cardiac injury Acute kidney injury acute respiratory distress age analyzed assessment Chest computed tomography China collected Complication coronavirus disease COVID‐19 COVID‐19 patient COVID‐19 patients COVID‐19 Critical Day death Deceased description Deterioration died disease course Disease progression disease progression pattern dysfunction enrolled Factor failure Hospitalization hospitals illness onset independent risk factor initial Laboratory laboratory data material Mortality objective Patient patients preexisting comorbidities preexisting comorbidity progression radiological Result risk factor SARS‐CoV‐2 Sepsis SOFA SOFA score survived surviving patient surviving patients syndrome variables
[DOI] 10.1002/iid3.343 PMC 바로가기 [Article Type] Original Research

High dose dexamethasone treatment for Acute Respiratory Distress Syndrome secondary to COVID-19: a structured summary of a study protocol for a randomised controlled trial

COVID-19에 따른 급성 호흡곤란 증후군에 대한 고용량 덱사메타손 치료: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약

Letter

Published on 2020-08-262022-08-13
Journal: Trials [Category] MERS, 임상,

[키워드] 1:1 active cancer acute respiratory distress acute respiratory distress syndrome Adult patients advance directives Advanced cancer age alpha error anticipated approved ARDS assessment assigned bilateral pulmonary infiltrates Blinding block breast-feeding Buenos Aires capture cardiac disease CEMIC clinical clinical trial code Complete concealed Confirmed COVID-19 COVID-19, Dexamethasone, Acute Respiratory Distress Syndrome, Randomised controlled trial, protocol, Steroids delirium develop Dexamethasone diagnosis of SARS-CoV-2 directive discharge disease dissemination do not resuscitate dose Effectiveness element End-Expiratory Pressure evaluate exclusion criteria Expiratory Pressure explained failure followed by Frequency glucocorticoid Glucocorticoids group hemodynamic High dose HIV infection hypoxemic Hypoxemic respiratory failure ICU Immunosuppression Immunosuppressive agents include inclusion criteria Infection Informed consent intensive care unit International legal guardian Length less Life expectancy local Ethics Committee mechanical ventilation Mortality multicenter muscle weakness Nosocomial infection Nosocomial infections number objective open open label open trial other disease other diseases outcome Palliative care PaO parallel group participant Participation Patient Patient care platform Pneumonia Positive end-expiratory pressure power power of 80% Prednisone pressure Prone position protocol R language random randomised randomised controlled trial randomization Randomized randomized clinical trial receive recruitment Registered renal renal disease respiratory respiratory distress Respiratory distress syndrome Respiratory failure resuscitate order RT-PCR Sample size SARS-COV-2 infection SARS-CoV-2 pneumonia secondary Secondary outcomes secondary to sequence Sequential Organ Failure Assessment severe immunosuppression SOFA Standard deviation status Stratified randomization Study protocol subject Support syndrome table terminal Terminal disease title Treatment treatment groups Trial Trial registration two-tailed alpha error Variation ventilator ventilator-free day Ventilator-free days ventilatory Version viral shedding weakness website women
[DOI] 10.1186/s13063-020-04646-y PMC 바로가기 [Article Type] Letter

Impact of Shenfu injection on a composite of organ dysfunction development in critically ill patients with coronavirus disease 2019 (COVID-19): A structured summary of a study protocol for a randomized controlled trial

Letter

Published on 2020-08-242022-10-29
Journal: Trials [Category] COVID-19, MERS,

[키워드] 1:1 28-day mortality 48 hours adopted allergic allergy allocation concealment alveolar baseline bleeding blinded Blinding block randomization both group breastfeeding women caused China Chinese clinical clinical trial conducted control group coronavirus disease COVID-19 criteria Critical Critically ill patient death defined determine Diagnosis dissemination distribution element enrolled enrolment event exacerbated expected HIV hospital hospital cost ICU immunosuppressive drug Impact incidence include increase in injection intensive care Length lung malignant tumor management guideline multicenter National Health Commission number objective Obstructive Open-label organ organ dysfunction Organ failure outcome parallel group participant Patient patient recruitment patients patients with COVID-19 Pneumonia pregnant primary endpoint protocol provided pulmonary interstitial fibrosis random randomised randomised controlled trial randomization Randomized Randomized controlled trial Randomly receive recruit recruited researchers Sample size SAS sealed secondary endpoint Sepsis Seven severe malnutrition severity Shenfu injection shown SOFA SOFA score statistical status study group Study protocol supportive therapy the patient Total treat Treatment Two-arm underlying disease usual care vasoactive drug Volume website
[DOI] 10.1186/s13063-020-04677-5 PMC 바로가기 [Article Type] Letter

Targeting Endothelial Dysfunction in Eight Extreme-Critically Ill Patients with COVID-19 Using the Anti-Adrenomedullin Antibody Adrecizumab (HAM8101)

Article

Published on 2020-08-112022-10-28
Journal: Biomolecules [Category] COVID-19, MERS,

[키워드] acute renal failure acute respiratory distress Administered administration Adrecizumab adrenomedullin antibody approach ARDS C-reactive protein calculated capillary leakage case sery coronavirus disease COVID-19 COVID-19 patient COVID-19 patients Critical Critically ill died discharged Efficacy eight endothelial function Endothelium expected FIVE Follow-up HAM 8101 High-dose highest humanized ICU Ill inflammatory parameter intensive care interleukin-6 life-threatening low-dose mechanical ventilation median monoclonal Mortality outcome paO2/fiO2 Patient patients procalcitonin ranged renal replacement therapy resource risk Sepsis Seven severity Shock single dose small sample size SOFA SOFA score suffered surviving patient syndrome targeting the disease the patient therapeutic Vascular with COVID-19
[DOI] 10.3390/biom10081171 PMC 바로가기 [Article Type] Article

Prominent coagulation disorder is closely related to inflammatory response and could be as a prognostic indicator for ICU patients with COVID-19

Article

Published on 2020-08-062022-10-30
Journal: Journal of Thrombosis and Thrombolysis [Category] COVID-19, SARS,

A phase II, single-center, double-blind, randomized placebo-controlled trial to explore the efficacy and safety of intravenous melatonin in patients with COVID-19 admitted to the intensive care unit (MelCOVID study): a structured summary of a study protocol for a randomized controlled trial

중환자실에 입원한 COVID-19 환자의 정맥 주사 멜라토닌의 효능과 안전성을 조사하기 위한 2상, 단일 센터, 이중 맹검, 무작위 위약 대조 시험(MelCOVID 연구): 연구 프로토콜의 구조화된 요약 무작위 대조 시험을 위해

Letter

Published on 2020-08-052022-08-13
Journal: Trials [Category] MERS, 임상,

[키워드] 6 hours Acute hypoxemic respiratory failure addition Admission Adult patients adverse effect adverse event adverse events age allocation anticipated Autoimmune disease Biochemical parameters blinded Blinding blood gas blood gas analysis body weight C-reactive protein Caregivers carried chronic Chronic kidney disease clinical condition clinical development commercialization comparator compatible symptom compatible symptoms Complete completion computer conducted Confirmed Consent Control control arm control group COVID-19 COVID-19-associated thromboembolic phenomena Critically ill D-dimer daily dose Date determined by disease dissemination double-blind Efficacy and safety element enzyme EU Clinical Trial evaluate evaluate the effect exclusion criteria expected experimental arm experimental group failing organ failing organs family member ferritin Frequency gas analysis GFR greater hematologic Hemodialysis hypoxemic Hypoxemic respiratory failure ICU ICU admission impairment Inclusion inclusion criteria increase in inflammatory state Informed institutional protocols intensive care intensive care unit interleukin interleukin-6 intravenous Kidney disease legal guardian less liver enzymes maximum mechanical ventilation medical illness melatonin Mortality multi-organ failure normal range number objective Organ failure outcome parameters participant Patient patient condition patients with COVID-19 per day performed phase physician Placebo placebo-controlled randomized trial plasma Plasma levels positive RT-PCR Pregnancy pregnancy test Prevent procalcitonin Program protocol provided randomization randomization sequence Randomized Randomized controlled trial randomized placebo-controlled trial receive recruited recruitment reduced reduction Respiratory failure Sample size SARS-COV-2 infection SAS version 9.4 SAS version 9.4 statistical software secondary Secondary objectives Sequential Organ Failure Assessment severity single center single-center SOFA Spain Stage Standard-of-care statistical status study drug study group study groups study period Study protocol systemic inflammatory response Terminal surgical thromboembolic Treatment Trial Trial registration two-arm parallel Ventilator-free days website with COVID-19 worsening written Informed Consent
[DOI] 10.1186/s13063-020-04632-4 PMC 바로가기 [Article Type] Letter

Clinical and Ethical Considerations in Allocation of Ventilators in an Influenza Pandemic or Other Public Health Disaster: A Comparison of the 2007 and 2015 New York State Ventilator Allocation Guidelines

Concepts in Disaster Medicine

Published on 2020-07-142022-10-31
Journal: Disaster Medicine and Public Health Preparedness [Category] Coronavirus, MERS, SARS,